跳至主要内容
临床试验/NL-OMON38362
NL-OMON38362已完成3 期

Rheos(TM) Pivotal Trial, a Study of Baroreflex Hypertension Therapy in Refractory Hypertension. Amendment 1: Dynamic cerebral autoregulation and lacol pulsewave velocity. Amendment 2: Investigational Plan , revision D Amendment 3: Investigational Plan, revision E Amendment 4: Investigational Plan, revision F - Rheos(TM) Pivotal Trial

CVRx Inc0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
CVRx Inc
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Ten minste 21 jaar en niet ouder dan 80 jaar
  • Office blood pressure equal or above 160/80 mmHg
  • Ambulatory 24-hour systolic blood pressure equal or above 135 mmHg
  • Normal anatomy of carotid artery bifurcations
  • Full doses of anti-hypertensive treatment (3 medication with 1 diuretic)
  • Compliant to therapy
  • Not pregnant or contemplating pregnancy during study period

排除标准

  • Known or suspected baroreflex failure or autonomic neuropathy
  • Body Mass Index above 45
  • Myocardial infarction, unstable angina, syncope or CVA within the past 3 months
  • Carotid atherosclerosis producing a 50% or greater reduction in diameter
  • Prior surgery, radiation or endobvascular stent placement in carotid sinus region
  • Severe chronic kidney disease, estimated GFR below 30 ml/min

研究者

发起方
CVRx Inc

相似试验